| P/E (FY) | — | Sales (TTM) | NOK 531.4M |
| Earnings (TTM) | -NOK 5.5M | ROE | −2.60% |
| Net Margin | −1.03% | ROIC | 8.27% |
| Debt / Equity | 0.53 | TD / EBITDA | 1.58 |
| EPS Growth 3Y | — | Sales Growth 3Y | 24.04% |
Navamedic ASA is a pharmaceutical company that develops, produces, markets, and sells medicines and related products across Norway, Sweden, Denmark, Finland, the Netherlands, and other markets. Its range covers prescription and over-the-counter drugs, medical nutrition for metabolic disorders, medical devices, food supplements, and cosmetics, along with consumer health items and antibiotics. The company distributes to hospitals, pharmacies, and patients. Formerly Glucomed AS, it is headquartered in Oslo.
| Market Cap | — | Trading Days | 4068 |
| 52W High | 27.90 |
| 52W Low | 15.70 |
| % Off High | −41.76% |
| YTD | −31.72% | 1Y | −32.01% |
| 3Y | −55.60% | 5Y | −20.73% |
| 10Y | 103.20% | Since incept. (ann.) | 7.63% |
| Ann. Volatility (1Y) | 36.88% | Ann. Volatility (3Y) | 40.74% |
| Sharpe (1Y) | −0.90 | Sharpe (3Y) | −0.52 |
| Max Drawdown (1Y) | −40.53% | Max Drawdown (3Y) | −63.15% |
| Beta (3Y, vs SPY) | −0.08 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| LLY | ELI LILLY & Co | $1.15T | 53.2 |
| JNJ | JOHNSON & JOHNSON | $642.79B | 24.2 |
| ONC | BeOne Medicines Ltd. | $477.60B | 1739.3 |
| ABBV | AbbVie Inc. | $465.02B | 111.5 |
| MRK | Merck & Co., Inc. | $325.57B | 18.1 |
| AMGN | AMGEN INC | $212.16B | 27.6 |
| ABT | ABBOTT LABORATORIES | $186.84B | 28.8 |
| GILD | GILEAD SCIENCES, INC. | $166.77B | 19.8 |
| PFE | PFIZER INC | $143.91B | 18.6 |
| SYK | STRYKER CORP | $132.87B | 41.3 |
| BMY | BRISTOL MYERS SQUIBB CO | $129.88B | 18.4 |
| ISRG | INTUITIVE SURGICAL INC | $127.82B | 46.0 |
